Products for Research Use Only

CTAP (TFA)

CAT: 0804-HY-P1335A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P1335A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].
UNSPSC
12352209
Target
Opioid Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ctap-tfa.html
Purity
99.60
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@H](NC([C@H](CSSC(C)([C@H](NC([C@](NC([C@@H](NC1=O)CCCNC(N)=N)=O)([H])[C@H](O)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.OC(C(F)(F)F)=O.[x]
Molecular Formula
C51H69N13O11S2.xC2HF3O2
Molecular Weight
1104.30 (free base)
References & Citations
[1]Mitchell J Bartlett, et al. Highly-selective µ-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes|[2]Abbruscato TJ, et al. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther. 1997 Jan;280 (1) :402-9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
δ Opioid Receptor/DOR; μ Opioid Receptor/MOR

Popular Products